Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Evoke Pharma (EVOK)

Evoke Pharma (EVOK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,029
  • Shares Outstanding, K 8,478
  • Annual Sales, $ 5,180 K
  • Annual Income, $ -7,790 K
  • 60-Month Beta 0.22
  • Price/Sales 0.83
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade EVOK with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.33
  • Most Recent Earnings $-0.59 on 03/14/24
  • Latest Earnings Date 05/20/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4159 +13.01%
on 04/16/24
0.6750 -30.37%
on 04/01/24
-0.1500 (-24.19%)
since 03/15/24
3-Month
0.4159 +13.01%
on 04/16/24
0.8700 -45.98%
on 01/17/24
-0.3952 (-45.68%)
since 01/16/24
52-Week
0.4159 +13.01%
on 04/16/24
2.4200 -80.58%
on 04/20/23
-1.4700 (-75.77%)
since 04/14/23

Most Recent Stories

More News
Evoke Pharma Reports Second Quarter 2022 Financial Results

Total new inbound prescriptions over 500 for first time, 24% increase over Q1; New cumulative prescribers up 23%; Net revenue increased by 11%...

EVOK : 0.4700 (-1.09%)
Evoke Pharma to Report Second Quarter Results on August 10, 2022

SOLANA BEACH, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for...

EVOK : 0.4700 (-1.09%)
Evoke Pharma Recognizes Gastroparesis Awareness Month through its Support of The International Foundation for Gastrointestinal Disorders (IFFGD)

Ranked #1 in IFFGD Virtual Walk to spread awareness and support research for gastrointestinal disorders Evoke attending ANMS 2022 meeting August 5-7...

EVOK : 0.4700 (-1.09%)
Evoke Pharma Announces Approval of GIMOTI® to Florida State Medicaid Program

SOLANA BEACH, Calif., June 15, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on...

EVOK : 0.4700 (-1.09%)
Evoke Pharma Regains Compliance with Nasdaq Listing Requirements and Provides Financial Update

SOLANA BEACH, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on...

EVOK : 0.4700 (-1.09%)
Real-World Data Analysis Reveals a Lower Risk of Tardive Dyskinesia (TD) with Metoclopramide than Previously Reported

Presented as a Poster of Distinction at Digestive Disease Week (DDW) 2022, showed a 98.8 per 100,000 (0.1%) incidence of TD among gastroparesis patients...

EVOK : 0.4700 (-1.09%)
Evoke Pharma to Report First Quarter 2022 Financial Results on May 10, 2022

SOLANA BEACH, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for...

EVOK : 0.4700 (-1.09%)
Evoke Pharma Reports Fourth Quarter and Full Year 2021 Financial Results

Fourth-quarter net product sales from prescriptions increased by 46% to $361,000 versus Q3 Easing of COVID-19 restrictions helped fuel higher sales,...

EVOK : 0.4700 (-1.09%)
Evoke Pharma to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022

SOLANA BEACH, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for...

EVOK : 0.4700 (-1.09%)
Evoke Pharma and EVERSANA Announce Acceptance of Abstract for Poster of Distinction Presentation at Digestive Disease Week (DDW) May 2022

Revisiting the risk of tardive dyskinesia with metoclopramide use in diabetic gastroparesis: results of a real-world data driven epidemiology study...

EVOK : 0.4700 (-1.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke...

See More

Key Turning Points

3rd Resistance Point 0.5588
2nd Resistance Point 0.5194
1st Resistance Point 0.4947
Last Price 0.4700
1st Support Level 0.4306
2nd Support Level 0.3912
3rd Support Level 0.3665

See More

52-Week High 2.4200
Fibonacci 61.8% 1.6544
Fibonacci 50% 1.4180
Fibonacci 38.2% 1.1815
Last Price 0.4700
52-Week Low 0.4159

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar